The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) is a huge mover today! About 783,718 shares traded hands or 53.57% up from the average. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 69.45% since April 8, 2016 and is uptrending. It has outperformed by 63.80% the S&P500.
The move comes after 6 months positive chart setup for the $1.01B company. It was reported on Nov, 10 by Barchart.com. We have $12.86 PT which if reached, will make NASDAQ:CORT worth $444.40M more.
According to Zacks Investment Research, “Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol. It is developing its lead product, CORLUX for the treatment of the psychotic features of psychotic major depression. Corcept Therapeutics Incorporated is headquartered in Menlo Park, California.”
Insitutional Activity: The institutional sentiment increased to 1.8 in Q2 2016. Its up 0.57, from 1.23 in 2016Q1. The ratio increased, as 13 funds sold all Corcept Therapeutics Incorporated shares owned while 22 reduced positions. 24 funds bought stakes while 39 increased positions. They now own 45.31 million shares or 34.44% more from 33.70 million shares in 2016Q1.
Tiaa Cref Invest Mngmt Ltd Limited Liability Company has 0% invested in the company for 282,832 shares. Alliancebernstein Lp holds 0% or 223,320 shares in its portfolio. Federated Pa last reported 0.22% of its portfolio in the stock. Swiss Bancorp, a Switzerland-based fund reported 128,200 shares. Moreover, Invesco Limited has 0% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 1.34 million shares. Blackrock Gp has 0% invested in the company for 21,484 shares. Art Advisors Limited Co holds 0% or 13,053 shares in its portfolio. Thornburg Management holds 199,762 shares or 0.01% of its portfolio. Nomura last reported 0% of its portfolio in the stock. Aqr Capital Mgmt Ltd Liability Corp has 0% invested in the company for 96,804 shares. Zurcher Kantonalbank (Zurich Cantonalbank) last reported 2,319 shares in the company. First Eagle Invest Mngmt Ltd reported 223,935 shares or 0% of all its holdings. Blackrock Incorporated has 27,699 shares for 0% of their US portfolio. The Ontario – Canada-based Manufacturers Life Insurance Co The has invested 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Moreover, Blackrock Advsr Ltd Limited Liability Company has 0% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 37,135 shares.
Insider Transactions: Since November 7, 2016, the stock had 0 insider buys, and 1 insider sale for $4.15 million net activity. The insider BELANOFF JOSEPH K sold 500,000 shares worth $4.15M.
More recent Corcept Therapeutics Incorporated (NASDAQ:CORT) news were published by: Fool.com which released: “Corcept Therapeutics Rose 18% in March. Here’s Why.” on April 06, 2016. Also Fool.com published the news titled: “Why Corcept Therapeutics Incorporated Shares Were Mauled” on May 07, 2014. Seekingalpha.com‘s news article titled: “Corcept Therapeutics: Cushing’s Syndrome Is Just The Beginning” with publication date: October 11, 2016 was also an interesting one.
CORT Company Profile
Corcept Therapeutics Inc., incorporated on May 13, 1998, is a pharmaceutical firm engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders. The Firm is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). The Firm also has discovered approximately three structurally distinct series of selective cortisol modulators, all of which share mifepristone’s affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor, and so do not terminate pregnancy or cause other side effects associated with progesterone receptor antagonism. The Firm has begun pre-clinical and clinical development of its lead compounds from these series.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.